| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
4 |
/ |
2020 |
|
|
|
| |
Data sporządzenia: |
2020-01-28 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
The receipt of five year follow-up report by expert and consultant in Peripheral Nerve
Block _PNB_ Regional Anesthesia; provides validation and confidence to advance CompuFlo
in PNB market
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer"_,
today announced the receipt of a report by Dr. Olivier Choquet, a recognized international
expert on peripheral nerve blocks _PNB_ and a consultant to Milestone Scientific,
Inc., the majority shareholder and licensor of the Issuer, which concludes that the
CompuFlo® with Dynamic Pressure Sensing technology® is the only available device capable
of precisely measuring, displaying, warning, controlling and recording needle tip
pressure in real time to help reduce the risk of needle injury during PNB procedures.
Continuous peripheral nerve block procedures are becoming more prevalent, including
pain management for patients undergoing upper/lower extremity surgeries and patients
suffering from trauma. Additionally, peripheral nerve blocks are increasingly utilized
as an attractive alternative to opioids for pain management, including orthopedic
surgeries, which are considered one of the most painful surgeries.
Dr. Olivier Choquet is the Medical Director of the Emergency Surgery operating theater
and a Medical Doctor in the Department of Anesthesiology in Traumatology and Orthopedics,
Lapeyronie University hospital, Montpellier, France. He has more than 50 publications
to his name and is a sought after expert in the area of regional anesthesia. He lectures
internationally and conducts workshops at major Congresses on a regular basis. He
also serves as a clinical consultant to Milestone Scientific, Inc. and has been instrumental
identifying how CompuFlo’s Dynamic Pressure Sensing Technology can change how PNB
procedures are performed.
In 2015, Dr Choquet and his colleagues at Lapeyronie University hospital started exploring
the use of the CompuFlo technology for PNB procedures to assess the optimal flow rate
during PNB procedures. He went on to investigate using Dynamic Pressure Sensing
technology as a means of detecting direct needle-to-nerve contact using CompuFlo,
which he demonstrated. This initial research gave rise to the pursuit of developing
a true multimodal monitoring concept of combining ultrasound guidance, nerve stimulation
and CompuFlo Dynamic Pressure Sensing technology. A formal comparative clinical
study has been conducted and is currently in review for publication in a well-respected,
peer-reviewed medical journal.
Between 2016 thru 2019, Dr. Choquet and his colleagues conducted five additional research
projects, in which Milestone Scientific’s Dynamic Pressure Sensing technology has
been studied. The preliminary results of his research have been presented at national
meetings and, in 2016, he was awarded the Best Regional Anesthesia Abstract at the
French Anesthesia Society Annual Meeting. Since 2019, Dr. Choquet and colleagues
from the Lapeyronie University hospital Department of Paediatric and Gynecologic Anaesthesia
conducted an Observational Study using the CompuFlo technology in PNB and epidural
procedures in pediatric patients. Data collection is nearly complete and statistical
analysis is underway. This study will be submitted for publication in 2020.
The Board of Directors of the Company believes that although quite new, the concept
of injection pressure monitoring has seen rapid growth and will grow even further,
as evidenced by the introduction of several devices designed specifically for use
during regional anesthesia and the demonstration that CompuFlo with Dynamic Pressure
Sensing technology may prevent intraneural injection.
The Board of Directors of the Issuer is very excited about the research that Dr. Choquet
continues to conduct, as he is on the cutting edge of regional anesthesia and his
team is making important contributions to the field. The Board of Directors of the
Company is grateful that Dr. Choquet recognizes the value in CompuFlo technology and
has agreed to be part of the team. Overall, the PNB is a large, growing and untapped
market for CompuFlo technology. Although the Issuer remain laser focused on accelerating
the commercialization of the epidural instrument, the Company is now sufficiently
advanced that it is preparing the commercial pipeline in other indications.
|
|
|
RB_ASO: The receipt of five year follow-up report by expert and consultant in Peripheral Nerve
Block (PNB) Regional Anesthesia; provides validation and confidence to advance CompuFlo
in PNB market 
